FTSE All-Share
|
5 566,13
|
32,53
|
0,59 %
|
Analysen zu FTSE All-Share-Werten
| 02.04.26 | GSK Buy | Jefferies & Company Inc. | |
| 02.04.26 | Shell Buy | Jefferies & Company Inc. | |
| 02.04.26 | BP Hold | Jefferies & Company Inc. | |
| 02.04.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 02.04.26 | Rio Tinto Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 02.04.26 | Shell Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 02.04.26 | BP Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 02.04.26 | London Stock Exchange Buy | Jefferies & Company Inc. | |
| 01.04.26 | HSBC Holdings Buy | Goldman Sachs Group Inc. | |
| 01.04.26 | Unilever Hold | Deutsche Bank AG | |
| 01.04.26 | Unilever Overweight | Barclays Capital | |
| 01.04.26 | National Grid Buy | Deutsche Bank AG | |
| 01.04.26 | Unilever Overweight | JP Morgan Chase & Co. | |
| 01.04.26 | Diageo Buy | Jefferies & Company Inc. | |
| 01.04.26 | Unilever Outperform | Bernstein Research | |
| 01.04.26 | Unilever Underperform | Jefferies & Company Inc. | |
| 01.04.26 | Diageo Overweight | Barclays Capital | |
| 01.04.26 | BP Overweight | Barclays Capital | |
| 01.04.26 | National Grid Overweight | JP Morgan Chase & Co. | |
| 31.03.26 | Unilever Outperform | Bernstein Research | |
| 31.03.26 | AstraZeneca Overweight | Barclays Capital | |
| 31.03.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 31.03.26 | Unilever Underperform | Jefferies & Company Inc. | |
| 31.03.26 | Unilever Underperform | RBC Capital Markets | |
| 31.03.26 | AstraZeneca Buy | Jefferies & Company Inc. | |
| 31.03.26 | Unilever Overweight | JP Morgan Chase & Co. | |
| 31.03.26 | London Stock Exchange Overweight | JP Morgan Chase & Co. | |
| 31.03.26 | Shell Overweight | Barclays Capital | |
| 31.03.26 | BP Overweight | Barclays Capital | |
| 31.03.26 | AstraZeneca Overweight | Barclays Capital | |
| 31.03.26 | GSK Underweight | Barclays Capital | |
| 31.03.26 | Diageo Buy | Deutsche Bank AG | |
| 31.03.26 | Diageo Buy | Deutsche Bank AG | |
| 30.03.26 | Rio Tinto Equal-weight | Morgan Stanley | |
| 30.03.26 | AstraZeneca Sell | Deutsche Bank AG | |
| 30.03.26 | GSK Underweight | JP Morgan Chase & Co. | |
| 30.03.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 27.03.26 | AstraZeneca Overweight | Barclays Capital | |
| 27.03.26 | BAT Neutral | JP Morgan Chase & Co. | |
| 27.03.26 | AstraZeneca Buy | Jefferies & Company Inc. |
HOT STOCKS DER LETZTEN 3 TAGE
| Unilever | 5 |
| BP | 3 |
| Shell | 2 |
| National Grid | 2 |
| Diageo | 2 |
| GSK | 1 |
| AstraZeneca | 1 |
| Rio Tinto | 1 |
| London Stock Exchange | 1 |
| HSBC Holdings | 1 |
Analysen zu Aktien folgender Indizes
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.